| All Releases |
 |
May 20, 2013
Announcement Under Irish Takeover Rules Revision to Relevant Securities in Issue |
 |
 |
| |
DUBLIN, Ireland, May 20, 2013 (GLOBE NEWSWIRE) -- In accordance with Rule 2.10 of the Irish Takeover Rules, Warner Chilcott plc (Nasdaq:WCRX) (the "Company") confirms that, as of the close of business on May 15, 2013, the Company's issued share capital consisted of 250,922,431 ordinary shares, par value US$0.01 per share (the "Ordinary Shares"). Th... |
|
|
May 20, 2013
Actavis to Acquire Warner Chilcott to Create Premier $11 Billion Revenue Global Specialty Pharmaceutical Company |
|
|
| |
... |
|
|
May 13, 2013
Announcement Under Irish Takeover Rules Relevant Securities in Issue |
|
|
| |
DUBLIN, Ireland, May 13, 2013 (GLOBE NEWSWIRE) -- In accordance with Rule 2.10 of the Irish Takeover Rules, Warner Chilcott plc (Nasdaq:WCRX) (the "Company") confirms that, as of the close of business on May 10, 2013, the Company's issued share capital consisted of 250,890,863 ordinary shares, par value US$0.01 per share (the "Ordinary Shares"). Th... |
|
|
May 10, 2013
Warner Chilcott Statement Regarding Market Speculation |
|
|
| |
DUBLIN, Ireland, May 10, 2013 (GLOBE NEWSWIRE) -- Further to media speculation, the Board of Warner Chilcott plc (Nasdaq:WCRX) confirmed today that the Company is engaged in preliminary discussions with Actavis, Inc. regarding a potential business combination transaction. These discussions are at a preliminary stage and may or may not lead to an of... |
|
|
May 10, 2013
Warner Chilcott Reports Operating Results for the Quarter Ended March 31, 2013 |
|
|
| |
DUBLIN, Ireland, May 10, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced its results for the quarter ended March 31, 2013.
Total revenue in the quarter ended March 31, 2013 was $593 million, a decrease of $92 million, or 13%, compared to the quarter ended March 31, 2012. For the quarter ended March 31, 2013, the decre... |
|
|
May 9, 2013
Warner Chilcott Announces FDA Approval of New Oral Contraceptive |
|
|
| |
DUBLIN, Ireland, May 9, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that the United States Food and Drug Administration (FDA) has approved a new oral contraceptive, norethindrone acetate and ethinyl estradiol chewable tablets and ferrous fumarate tablets, for the prevention of pregnancy. This product does not currentl... |
|
|
May 7, 2013
Warner Chilcott Declares Semi-Annual Cash Dividend of $0.25 Per Share |
|
|
| |
DUBLIN, Ireland, May 7, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that its Board of Directors declared a semi-annual cash dividend in the amount of $0.25 per share, payable June 14, 2013, to shareholders of record at the close of business on May 31, 2013.
This is a semi-annual cash dividend declared under the Co... |
|
|
May 2, 2013
Warner Chilcott Announces Changes to Board of Directors |
|
|
| |
DUBLIN, Ireland, May 2, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that its Board of Directors has voted unanimously to appoint Paul Herendeen, the Company's Executive Vice President and Chief Financial Officer, to the Company's Board effective as of May 2, 2013. Mr. Herendeen will continue to serve as Executive Vice... |
|
|
May 1, 2013
Warner Chilcott Announces Earnings Release Date and Conference Call for First Quarter 2013 Financial Results |
|
|
| |
DUBLIN, Ireland, May 1, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that it will issue its first quarter 2013 financial results prior to the market opening on Friday, May 10, 2013.
In addition to issuing a press release, the Company will host a conference call for all interested parties on Friday, May 10, 2013 at ... |
|
|
April 22, 2013
Warner Chilcott Announces FDA Approval of New Oral Contraceptive |
|
|
| |
DUBLIN, Ireland, April 22, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that the United States Food and Drug Administration (FDA) has approved MINASTRINTM 24 FE (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) for the prevention of pregnancy. MINASTRIN 24 FE is manufactured for Warne... |
|
|
April 12, 2013
Warner Chilcott Announces FDA Approval of DORYX(R) Delayed-Release 200 mg Tablets |
|
|
| |
DUBLIN, Ireland, April 12, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that the United States Food and Drug Administration (FDA) has approved a 200 mg strength of DORYX® (doxycycline hyclate) Delayed-Release Tablets. DORYX Delayed-Release Tablets are a tetracycline-class oral antibiotic. The Company anticipates t... |
|
|
March 4, 2013
Warner Chilcott to Present at the 2013 Goldman Sachs Leveraged Finance Healthcare Conference |
|
|
| |
DUBLIN, Ireland, March 4, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that its Executive Vice President and Chief Financial Officer, Paul Herendeen, is scheduled to speak at the 2013 Goldman Sachs Leveraged Finance Healthcare Conference on Wednesday, March 6th at 1:20 p.m. EST.
The presentation will be simultaneou... |
|
|
February 22, 2013
Warner Chilcott to Present at the 2013 RBC Capital Markets Healthcare Conference |
|
|
| |
DUBLIN, Ireland, Feb. 22, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that its Executive Vice President and Chief Financial Officer, Paul Herendeen, is scheduled to speak at the 2013 RBC Capital Markets Healthcare Conference on Wednesday, February 27th at 8:00 a.m. EST.
The presentation will be simultaneously webc... |
|
|
February 22, 2013
Warner Chilcott to Present at the 2013 Citi Global Healthcare Conference |
|
|
| |
DUBLIN, Ireland, Feb. 22, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that its Executive Vice President and Chief Financial Officer, Paul Herendeen, is scheduled to speak at the 2013 Citi Global Healthcare Conference on Tuesday, February 26th at 1:30 p.m. EST.
The presentation will be simultaneously webcast at htt... |
|
|
February 22, 2013
Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2012 |
|
|
| |
DUBLIN, Ireland, Feb. 22, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced its results for the quarter and year ended December 31, 2012.
Total revenue in the quarter ended December 31, 2012 was $612 million, a decrease of $34 million, or 5%, compared to the quarter ended December 31, 2011. For the quarter ended Decembe... |
|
|
February 18, 2013
Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2012 Financial Results |
|
|
| |
DUBLIN, Ireland, Feb. 18, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that it will issue its fourth quarter and full year 2012 financial results prior to the market opening on Friday, February 22, 2013.
In addition to issuing a press release, the Company will host a conference call for all interested parties on Fr... |
|
|
February 8, 2013
Warner Chilcott Announces 2013 Financial Guidance |
|
|
| |
DUBLIN, Ireland, Feb. 8, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced its view of anticipated full year 2013 financial results.
Total revenue for 2013 is expected to be in the range of $2.3 to $2.4 billion. The 2013 revenue expectations reflect, among other things, the anticipated growth of certain of the Company's... |
|
|
February 5, 2013
Warner Chilcott Announces FDA Approval of New Ulcerative Colitis Product |
|
|
| |
DUBLIN, Ireland, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that the United States Food and Drug Administration (FDA) has approved its new 400 mg mesalamine product indicated for the treatment of ulcerative colitis. The product will be marketed as DELZICOL™ (mesalamine) 400 mg delayed-release capsules. ... |
|
|
February 4, 2013
Warner Chilcott Announces 2013 Financial Guidance Conference Call |
|
|
| |
DUBLIN, Ireland, Feb. 4, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that it will issue its 2013 financial guidance prior to the market opening on Friday, February 8, 2013.
In addition to issuing a press release, the Company will host a conference call for all interested parties on Friday, February 8 at 8:00 a.m. ... |
|
|
January 2, 2013
Warner Chilcott to Present at the 31st Annual J.P. Morgan Healthcare Conference |
|
|
| |
DUBLIN, Ireland, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that Roger Boissonneault, President and Chief Executive Officer, and Paul Herendeen, Executive Vice President and Chief Financial Officer, are scheduled to speak at the 31st Annual J.P. Morgan Healthcare Conference on Tuesday, January 8th at 7:30 a.m... |
|
|
|
Investor Relations
